It is prescribed for individuals with obesity or those who have weight-related health conditions
B.W., body weight
The FDA has reported 90 cases of ileus (bowel obstruction) linked to GLP-1 medications, leading to updated warnings on medication labels
Our commitment to your health and well-being means you can trust us to help you achieve your weight loss goals
De Block CEM, Drinck E, Verhaegen A, van Gaal LF (2022) Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
Still, the FDA stood its ground, giving 503A facilities until February 18 to stop production, and 503Bs until March 19but it wasnt going to enforce any of this while the lawsuit was pending